Loading patent…
AssigneeThe Regents of the University of California
InventorsNancy E. Lane, Ruiwu Liu, Wei Yao, Kit S. Lam
Estimating the term…
The present invention provides methods of treating a subject having a primary inflammatory disease or disorder comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, wherein the composition comprising the LLP2A-bisphosphonate conjugate enhances the delivery of mesenchymal stem cells to a site of inflammation. Methods of enhancing an anti-inflammatory or immunomodulatory property of mesenchymal stem cells, comprising administering to a subject in need thereof the mesenchymal stem cells and a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, are also provided.
A method of treating a subject having a primary inflammatory disease or disorder selected from arthritis, inflammatory arthritis, rheumatoid arthritis, synovitis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, spondylarthritis, and osteoarthritis, the method comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, wherein the composition comprising the conjugate enhances the delivery of mesenchymal stem cells to a site of inflammation.
A method of reducing inflammation in a subject in need thereof, the method comprising co-administering to the subject (a) a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, and (b) mesenchymal stem cells, wherein the composition comprising the conjugate enhances the delivery of the mesenchymal stem cells to a site of inflammation.
A method of treating a subject having an inflammatory disease or disorder, the method comprising co-administering to the subject (a) a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, and (b) mesenchymal stem cells, wherein the amount of mesenchymal stem cells that is administered is a subtherapeutic dose.
A method of enhancing an anti-inflammatory or immunomodulatory property of mesenchymal stem cells, comprising administering to a subject in need thereof the mesenchymal stem cells and a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug.
A method of reducing one or more signs or symptoms of arthritis pain in a subject, the method comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug.
A method of reducing, slowing, or inhibiting cartilage and/or bone destruction resulting from inflammation in arthritis, the method comprising administering to the subject a composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug.
Dependencies are inferred from the claim text.